POS1216 EFFECT OF GENDER AND FOLLOW-UP TIME IN DAMAGE ACCRUAL: DATA FROM A LATIN AMERICA LUPUS COHORT

Le résumé fourni par la source

Background: Previous studies have shown that male gender is an independent predictor of organ damage in patients with systemic lupus erythematosus (SLE), particularly in the early stages of their disease [1, 2]. In the previous GLADEL cohort, male patients had a higher SDI (SLICC/ACR Damage Index) than their female counterparts, although this difference was not statistically significant [3]. Objectives: To assess organ damage, as measured by the SDI, as a function of gender in the GLADEL 2.0 cohort. Methods: Study population: A total of 43 centers from 10 Latin American countries enrolled patients 18 years of age or older who met the 1982/1997 ACR and/or 2012 SLICC classification criteria. Statistical analysis: Descriptive analyses were conducted. An interaction analysis between gender and time was performed using a mixed-effects model in R. SDI was the dependent variable, while gender (between-subjects) and time (within-subjects) were the independent variables. A random intercept per participant was included to account for within-subject variability. Logistic regression modeling was used to examine the factors associated with changes in the SDI from baseline to the end of follow-up. A significance level of 5% was applied to all analyses and R version 4.4.0 software was used. Results: Of the 1081 patients enrolled in the GLADEL 2.0 cohort, 385 patients matched by gender were considered. Of these, 190 completed at least four annual visits and were included in these analyses. Seventy percent of patients were women and 30% were men (Table 1). No statistically significant differences in organ damage, as measured by the SDI, were found between male and female patients ( p = 0.563). This trend remained consistent throughout the follow-up period, with no significant interactions observed ( p = 0.90). Damage accumulation over time increased significantly in both sexes (Figure 1A). The affected SDI domain frequency was examined both at baseline and during follow-up (Figure 1B). In general, males had a higher occurrence of ocular and cutaneous, and a moderate increase in malignant involvement compared to females, whereas females had a higher frequency of gastrointestinal, gonadal failure, pulmonary, peripheral vascular and musculoskeletal involvement. After adjusting for sociodemographic and clinical/immunologic characteristics, multivariate analysis revealed that disease duration (OR: 1.05; 95%CI: 1.0-1.1) and disease activity, as measured by the SLEDAI-2K (OR: 1.05; 95%CI: 1.0-1.1), were associated with a higher likelihood of an increase in SDI. Conclusion: Although male gender was not associated with an increased risk of damage accumulation, the proportion of patients with an increased SDI was higher in males than in their females. Organ damage during follow-up increased significantly increased in both sexes. As patients in this cohort continue to be closely monitored, the impact of gender on damage accumulation may become more evident. REFERENCES: [1] Bruce IN, et al. Ann Rheum Dis . 2015;74:1706-13. [2] Andrade RM, et al . Arthritis Rheum . 2007;56:622-30. [3] MA García, et al. Lupus . 2005;14;938-046. Table 1. Sociodemographic and clinical characteristics of patients with SLE by gender Figure 1(A) Mean SLICC/ACR score and (B) frequency of manifestations by SDI area by gender and follow-up time. Acknowledgements: NIL . Disclosure of Interests: Diana Fernández-Ávila: None declared, Rosana Quintana: None declared, Karen Roberts: None declared, Romina Nieto: None declared, Marina Scolnik GSK, Astrazeneca, Janssen, Roche, Pfizer, GSK, Astrazeneca, Janssen, Roche, Pfizer, Carmen Funes Soaje: None declared, Cintia Otaduy: None declared, Verónica Saurit: None declared, Valeria Arturi: None declared, Guillermo Berbotto: None declared, María Constanza Bertolaccini: None declared, Eduardo Kerzberg: None declared, Maria de los Ángeles Gargiulo: None declared, Cecilia Pisoni: None declared, Ana Carolina Ralle: None declared, Joaquín Martínez Serventi: None declared, Ana Carolina de Oliveira e Silva Montandon GSK, AstraZeneca, Odirlei André Monticielo: None declared, Henrique Ataide Mariz: None declared, Laissa Alvino: None declared, Eduardo F. Borba: None declared, Emily Neves: None declared, Edgard Torres dos Reis Neto: None declared, Iris Guerra Herrera: None declared, Milena Mimica Davet: None declared, Gustavo Aroca Martinez: None declared, Antonio Iglesias Gamarra: None declared, Carlos A. Cañas Davila: None declared, Gerardo Quintana-Lopez: None declared, Carlos Enrique Toro-Gutierrez: None declared, Mario Moreno Alvarez: None declared, Olga L. Vera Lastra: None declared, Margarita Portela Hernandez: None declared, Hilda Fragoso Loyo: None declared, Luis Silveira: None declared, Yelitza González Bello: None declared, Carlos Abud Mendoza: None declared, Jorge Antonio Esquivel-Valerio: None declared, Marcelo Barrios: None declared, Lourdes Carolina Vázquez: None declared, Magaly Alva: None declared, Manuel F. Ugarte-Gil Advisory Boards - AstraZeneca and Ferrer, GSK and AstraZeneca, Janssen, Armando Calvo Quiróz: None declared, Roberto Muñoz Louis: None declared, Carina Pizzarossa: None declared, Gonzalo Silveira: None declared, Federico Zazzetti Johnson & Johnson, Johnson & Johnson, Ashley Orillion Johnson & Johnson, Johnson & Johnson, Urbano Sbarigia Johnson & Johnson, Johnson & Johnson, Graciela S. Alarcón: None declared, Bernardo Pons-Estel AstraZeneca, GSK, Janssen, Guillermo Pons-Estel AstraZeneca, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer, RemeGen, Sanofi and Werfen Diagnostics, AstraZeneca, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer, RemeGen, Sanofi and Werfen Diagnostics, AstraZeneca, Boehringer Ingelheim, GSK, Janssen, Novartis, Pfizer, RemeGen, Sanofi and Werfen Diagnostics. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.